Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide: a novel template for anticancer drugs.

D Stirling1

  • 1Celgene Corporation, 7 Powder Horn Drive, Warren, NJ 07059, USA.

Seminars in Oncology
|December 12, 2001
PubMed
Summary

New immunomodulatory drugs (IMiDs) are potent thalidomide analogs. These novel agents, like CDC-501, show promise in regulating immune responses and are under investigation for various conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Moving into the mainstream: healthcare professionals' views of implementing treatment focussed genetic testing in breast cancer care.

Familial cancer·2019
Same author

Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience.

BJOG : an international journal of obstetrics and gynaecology·2018
Same author

Current practice and factors influencing the provision of periodontal healthcare in primary dental care in Scotland: an explorative study.

British dental journal·2015
Same author

Is further intervention required to translate caries prevention and management recommendations into practice?

British dental journal·2015
Same author

A cautionary lesson on the use of targeted methods for EGFR mutation analysis: a case report.

Journal of clinical pathology·2014
Same author

Genetic mutations in patients with possible familial hypercholesterolaemia in South East Scotland.

Scottish medical journal·2012

Area of Science:

  • Immunology
  • Pharmacology
  • Oncology

Background:

  • Thalidomide is an approved immunomodulatory agent for erythema nodosum leprosum (ENL).
  • It is being investigated for various malignancies and immune disorders.
  • Structural analogs, including immunomodulatory drugs (IMiDs), have been developed to enhance therapeutic potential and understand molecular targets.

Purpose of the Study:

  • To explore structural analogs of thalidomide for new therapeutics.
  • To investigate the potency and effects of IMiDs compared to thalidomide.
  • To evaluate the safety and clinical development of the IMiD CDC-501.

Main Methods:

  • Synthesis of thalidomide structural analogs (IMiDs).
  • Assessment of IMiD potency in regulating cytokine production and T-cell proliferation.
  • Clinical evaluation of CDC-501 safety and efficacy in Phase I/II studies.

Main Results:

  • IMiDs are 100 to 1,000 times more potent than thalidomide in regulating cytokine production.
  • The effects of IMiDs and thalidomide (inhibitory or stimulatory) depend on the stimulus and cell type.
  • CDC-501 was safely administered in single and multiple doses to volunteers.

Conclusions:

  • IMiDs represent a more potent class of thalidomide analogs.
  • CDC-501 has demonstrated a safe profile in early clinical trials.
  • Further Phase I/II studies of CDC-501 in multiple myeloma are ongoing.

Related Experiment Videos